T淋巴细胞对于非小细胞肺癌免疫治疗的预后意义

非小细胞肺癌(NSCLC)是一种死亡率很高的全球性肿瘤,严重威胁着人类的生命和健康。非小细胞肺癌的治疗包括手术、化疗、放疗、靶向治疗、免疫治疗等。目前,免疫疗法已显示出巨大的潜力。但一部分人并没有受益,存在原发性耐药、免疫相关不良事件等问题。迫切需要一种有效的标志物来筛选受益人群并判断预后。迄今为止,FDA (食品和药物管理局)唯一批准的ICI反应的生物标志物PD-L1已在临床实践中全面实施。随着进一步的研究发现PD-L1具有一定的局限性,其他相关的生物标志物仍在探索和开发中。近年来,对T淋巴细胞的研究逐渐增多,其在预后中的作用已被广泛证实。本文就非小细胞肺癌免疫治疗的现状及T淋巴细胞预后标志物的意义进行综述。Non-small cell lung cancer (NSCLC) is a global tumor with a high mortality rate, which seriously threatens human life and health. The treatment of non-small cell lung cancer includes surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. At present, immunotherapy has shown great potential. Although immunotherapy has a good effect, some people do not benefit. There are problems such as primary drug resistance and immune-related adverse events. There is an urgent need for an effective marker to screen the beneficiary population and determine the prognosis. To date, the only FDA-approved biomarker for ICI response, PD-L1, has been fully implemented in clinical practice. As further studies have found that PD-L1 has certain limitations, other related biomarkers are still being explored and developed. In recent years, the research on T lymphocytes has gradually increased, which has a certain guiding significance for the prognosis of patients with non-small cell lung cancer. Its important role in the prognosis has been widely confirmed. This article reviews the current status of immunotherapy for non-small cell lung cancer and the significance of T lymphocyte prognostic markers.

晚期非小细胞肺癌免疫治疗中ctDNA的动态监测的现状与未来

非小细胞肺癌仍然是全球对人类危害最大的疾病之一,免疫治疗自问世就给晚期非小细胞肺癌患者带来了前所未有的益处。免疫治疗虽然在大跨步的飞速发展,但是仍然有一部分人无法获益,一种可靠且易于重复检测的判断疗效方法则显得尤为重要。ctDNA检测作为一种非侵入性检查,具有易于重复操作、特异性较强的优势,在不同类型肿瘤中的价值被普遍认可。ctDNA的动态监测也对免疫治疗过程中疗效的评估以及预后的发展发挥着十分重要的作用。与此同时,ctDNA在监测过程中的检测时间点、量化标准、各个检测方法的共识有待也进一步商榷。